title: Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane: a 2-year follow-up study.
abstract: OBJECTIVE
  Patients with chronic renal failure treated by hemodialysis develop lipoprotein abnormalities that may contribute to their increased risk ofatherosclerosis. This study shows lipid parameter follow-up procedure according to the type of dialysis membrane in an unselected population of 33 hemodialysis patients.
  
  
  METHODS
  The study included 33 patients with end-stage renal disease and 110 healthy blood bank donors of Tenon Hospital. Cholesterol and triglycerides were determined by enzymatic methods, apoA-I, apoB by immunoturbidimetry and Lp(a) by immunonephelemetry. Apo(a) phenotyping was performed by agarose gel electrophoresis followed by immunoblotting. Patients and controls subjects were estimated by Student's t- and chi2-tests.
  
  
  RESULTS
  Patients dialyzed with low-flux membranes had Lp(a) concentrations higher than patients dialyzed with high-flux membranes. Patients dialyzed with polyacrylonitrile membranes (AN 69) had an apoA-I concentration significantly lower than patients dialyzed with hemophane or polysulfone membranes. We also confirmed some of the lipid abnormalities and high Lp(a) concentrations in ESRD patients.
  
  
  CONCLUSIONS
  These results may contribute to a more rational choice of the dialysis membrane in hemodialysis patients.
authors.affiliation: Service de Biochimie, Hôpital Tenon, Paris, France.
authors.forename: M E
authors.initials: ME
authors.lastname: Diop
authors.forename: B
authors.initials: B
authors.lastname: Viron
authors.forename: S
authors.initials: S
authors.lastname: Bailleul
authors.forename: G
authors.initials: G
authors.lastname: Lefevre
authors.forename: H
authors.initials: H
authors.lastname: Fessi
authors.forename: J
authors.initials: J
authors.lastname: Maury
authors.forename: J
authors.initials: J
authors.lastname: Etienne
authors.forename: R
authors.initials: R
authors.lastname: Couderc
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D017270:Lipoprotein(a); D008567:Membranes, Artificial